查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1684647

抗 VEGF 治疗市场机会、成长动力、产业趋势分析与 2025 - 2034 年预测

Anti-VEGF Therapeutics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034
出版日期: | 出版商: Global Market Insights Inc. | 英文 130 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2024 年全球抗 VEGF 治疗市场价值为 138 亿美元，预计将稳定成长，预计 2025 年至 2034 年的复合年增长率为 1.9%。这一增长主要受多种因素推动，例如眼部疾病患病率不断上升、全球人口老化以及对可用治疗方案的认识不断提高。老年黄斑部病变 (AMD)、糖尿病视网膜病变和视网膜静脉阻塞是推动抗 VEGF 疗法需求的主要疾病。这些疾病通常与血管异常生长有关，可以使用 VEGF 抑制剂有效治疗。由于这些疗法显着改善了视力和整体疾病管理，它们已成为眼科的重要组成部分。

抗 VEGF 治疗市场 - IMG1

市场受到关键细分领域的影响，包括提供令人印象深刻的临床结果和更长的给药间隔的着名抗 VEGF 疗法。 2024 年，一种此类疗法由于减少了注射频率，提高了患者的便利性和对治疗方案的依从性，占据了 46.6% 的市场份额。由于注射次数较少，该疗法成为医疗保健提供者的首选，并促进了其日益广泛的应用。

市场范围
起始年份 2024
预测年份 2025-2034
起始值 138亿美元
预测值 166亿美元
复合年增长率 1.9％

从应用方面来看，黄斑水肿、糖尿病视网膜病变、视网膜静脉阻塞、AMD、近视脉络膜新生血管是市场的主要类别。黄斑水肿通常由糖尿病和血管併发症引起，2024 年该疾病占 47.5% 的市场份额，占据市场主导地位。全球糖尿病盛行率的上升加剧了黄斑水肿的发生，推动了对针对性治疗的需求增加。随着越来越多的患者被诊断出患有这种疾病并接受治疗，盛行率的变化是推动成长的重要动力，导致治疗需求显着上升。

在美国，受人口老化和视网膜疾病高发生率的推动，抗 VEGF 治疗市场规模将在 2024 年达到 51 亿美元。 AMD 仍然是导致视力障碍的主要原因之一，在市场扩张中发挥着至关重要的作用。美国先进的医疗保健体系确保患者能够广泛接受尖端治疗，并透过全面的报销框架提供支援。这种可及性使更多患者受益于抗 VEGF 疗法，巩固了美国在全球市场的主导地位。

目录

第 1 章：方法论与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业衝击力
    • 成长动力
      • 眼部疾病发生率不断上升
      • 老龄人口增加
      • 药物开发的技术进步
      • 人们越来越意识到及时治疗眼科疾病
    • 产业陷阱与挑战
      • 治疗费用高昂
      • 副作用和安全问题
  • 成长潜力分析
  • 监管格局
  • 技术格局
  • 未来市场趋势
  • 差距分析
  • 波特的分析
  • PESTEL 分析

第四章：竞争格局

  • 介绍
  • 公司市占率分析
  • 公司矩阵分析
  • 主要市场参与者的竞争分析
  • 竞争定位矩阵
  • 策略仪表板

第 5 章：市场估计与预测：按产品，2021 年至 2034 年

  • 主要趋势
  • 艾莉娅
  • 路欣迪
  • 贝奥武
  • 瓦比斯莫
  • 其他产品

第 6 章：市场估计与预测：按应用，2021 年至 2034 年

  • 主要趋势
  • 黄斑水肿
  • 糖尿病视网膜病变
  • 视网膜静脉阻塞
  • 老年性黄斑部病变
  • 近视脉络膜新生血管

第 7 章：市场估计与预测：按地区，2021 年至 2034 年

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第八章：公司简介

  • Alcon
  • Amgen
  • Bausch Health Companies
  • Bayer
  • Biogen
  • Bristol-Myers Squibb
  • Coherus BioSciences
  • Eli Lilly and Company
  • F. Hoffmann-La Roche
  • Hoya Corporation
  • Novartis
  • Pfizer
  • Regeneron Pharmaceuticals
  • Sanofi
  • Viatris
简介目录
Product Code: 13062

The Global Anti-VEGF Therapeutics Market, valued at USD 13.8 billion in 2024, is poised to expand steadily with a projected CAGR of 1.9% from 2025 to 2034. This growth is primarily driven by a combination of factors such as the increasing prevalence of eye diseases, the aging global population, and heightened awareness surrounding available treatment options. Age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion are among the leading conditions fueling the demand for anti-VEGF therapies. These diseases are typically associated with abnormal blood vessel growth, which can be effectively treated using VEGF inhibitors. As these therapies offer significant improvements in vision and overall disease management, they have become an essential part of ophthalmology.

Anti-VEGF Therapeutics Market - IMG1

The market is being shaped by key segments, including prominent anti-VEGF therapies that offer impressive clinical outcomes and longer dosing intervals. In 2024, one such therapy captured a substantial 46.6% market share due to its reduced injection frequency, enhancing patient convenience and adherence to treatment regimens. The ability to receive fewer injections has made this therapy the preferred choice among healthcare providers, contributing to its growing adoption.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$13.8 Billion
Forecast Value$16.6 Billion
CAGR1.9%

In terms of application, macular edema, diabetic retinopathy, retinal vein occlusion, AMD, and myopic choroidal neovascularization represent the main categories within the market. Macular edema, which often results from diabetes and vascular complications, led the market with a 47.5% share in 2024. The rising global prevalence of diabetes has exacerbated the occurrence of macular edema, driving an increased demand for targeted treatments. This shift in prevalence is a significant driver of growth, as more patients are diagnosed and treated for the condition, resulting in a notable uptick in therapeutic needs.

In the U.S., the anti-VEGF therapeutics market reached USD 5.1 billion in 2024, driven by the country's aging population and the high incidence of retinal disorders. AMD remains one of the leading causes of vision impairment, playing a crucial role in market expansion. The advanced healthcare system in the U.S. ensures that patients have broad access to cutting-edge treatments, bolstered by a comprehensive reimbursement framework. This accessibility has allowed more patients to benefit from anti-VEGF therapies, solidifying the U.S. as a dominant force within the global market.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates and calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 3600 synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing prevalence of eye diseases
      • 3.2.1.2 Rise in aging population
      • 3.2.1.3 Technological advancements in drug development
      • 3.2.1.4 Growing awareness towards timely treatment of ophthalmic disorders
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 High cost of treatment
      • 3.2.2.2 Side effects and safety concerns
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Technological landscape
  • 3.6 Future market trends
  • 3.7 Gap analysis
  • 3.8 Porter's analysis
  • 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 – 2034 ($ Mn)

  • 5.1 Key trends
  • 5.2 Eylea
  • 5.3 Lucentis
  • 5.4 Beovu
  • 5.5 Vabysmo
  • 5.6 Other products

Chapter 6 Market Estimates and Forecast, By Application, 2021 – 2034 ($ Mn)

  • 6.1 Key trends
  • 6.2 Macular edema
  • 6.3 Diabetic retinopathy
  • 6.4 Retinal vein occlusion
  • 6.5 Age-related macular degeneration
  • 6.6 Myopic choroidal neovascularization

Chapter 7 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

  • 7.1 Key trends
  • 7.2 North America
    • 7.2.1 U.S.
    • 7.2.2 Canada
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 UK
    • 7.3.3 France
    • 7.3.4 Spain
    • 7.3.5 Italy
  • 7.4 Asia Pacific
    • 7.4.1 China
    • 7.4.2 Japan
    • 7.4.3 India
    • 7.4.4 Australia
    • 7.4.5 South Korea
  • 7.5 Latin America
    • 7.5.1 Brazil
    • 7.5.2 Mexico
    • 7.5.3 Argentina
  • 7.6 Middle East and Africa
    • 7.6.1 South Africa
    • 7.6.2 Saudi Arabia
    • 7.6.3 UAE

Chapter 8 Company Profiles

  • 8.1 Alcon
  • 8.2 Amgen
  • 8.3 Bausch Health Companies
  • 8.4 Bayer
  • 8.5 Biogen
  • 8.6 Bristol-Myers Squibb
  • 8.7 Coherus BioSciences
  • 8.8 Eli Lilly and Company
  • 8.9 F. Hoffmann-La Roche
  • 8.10 Hoya Corporation
  • 8.11 Novartis
  • 8.12 Pfizer
  • 8.13 Regeneron Pharmaceuticals
  • 8.14 Sanofi
  • 8.15 Viatris